NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis

Background: The oncogenicity of neural precursor cell-expressed developmentally down-regulated 9 (NEDD9) has been demonstrated in multiple cancer types. However, the prognostic value of NEDD9 in some solid cancers remains controversial. Thus, this meta-analysis was conducted to evaluate the relationship between NEDD9 expression survival rates in solid tumors. Method: Our meta-analysis included studies searched from various search engines with speci fi c inclusion criteria and exclusion criteria. Combined HRs for overall survival (OS) and disease-free survival (DFS) or progression-free survival (PFS) or recurrence-free survival (RFS) or cancer-speci fi c survival (CSS) were assessed using fi xed-effects and random-effects models. The source of heterogeneity was identi fi ed by subgroup analysis. Additionally, publication bias was assessed using funnel plot and Egger ’ s regression asymmetry test. Result: Eighteen studies with a total of 2,476 patients were retrieved for analysis. Pooled HRs and 95% CIs were calculated. Both OS (HR=1.82; 95% CI: 1.43 – 2.31) and DFS/PFS/ RFS/CSS (HR=2.54; 95% CI: 1.93 – 3.33) indicated that NEDD9 overexpression is associated with poor OS in cancer patients with solid tumors. Conclusion: NEDD9 overexpression might be a potential marker to predict prognosis in solid cancer patients.

[1]  F. Tas,et al.  Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer , 2018, Biomolecules.

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  Jilin Li,et al.  Comprehensive analysis of metastasis-related genes reveals a gene signature predicting the survival of colon cancer patients , 2018, PeerJ.

[4]  J. Ostojić,et al.  EXPRESSION OF NEDD9 IN TRANSBRONCHIAL BIOPSIES OF LUNG ADENOCARCINOMA , 2018, Acta clinica Croatica.

[5]  A. Ragab,et al.  The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer. , 2018, Urologic oncology.

[6]  F. Tas,et al.  Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma. , 2017, Molecular and clinical oncology.

[7]  Jue Wang,et al.  Overexpression of NEDD9 in renal cell carcinoma is associated with tumor migration and invasion , 2017, Oncology letters.

[8]  O. Harb,et al.  The Prognostic Role of NEDD9 and P38 Protein Expression Levels in Urinary Bladder Transitional Cell Carcinoma , 2017, Journal of oncology.

[9]  T. Sun,et al.  The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients , 2016, OncoTargets and therapy.

[10]  H. Oguz,et al.  Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  Liang Zhou,et al.  Expression of NEDD9 in hepatocellular carcinoma and its clinical significance. , 2015, Oncology reports.

[12]  Dahong Zhang,et al.  High expression of HEF1 is associated with poor prognosis in urinary bladder carcinoma , 2014, OncoTargets and therapy.

[13]  Jun Zhang,et al.  Overexpression of Nedd9 is a prognostic marker of human gastric cancer , 2014, Medical Oncology.

[14]  Hongda Wang,et al.  NEDD9 promotes lung cancer metastasis through epithelial–mesenchymal transition , 2014, International journal of cancer.

[15]  Chao Liu,et al.  High expression of NEDD9 predicts adverse outcomes of colorectal cancer patients. , 2014, International journal of clinical and experimental pathology.

[16]  Jian-Wei Zhu,et al.  NEDD9 overexpression correlates with poor prognosis in gastric cancer , 2014, Tumor Biology.

[17]  L. Jia,et al.  NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer. , 2014, Human pathology.

[18]  Feiran Wang,et al.  NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma , 2014, Medical Oncology.

[19]  Zhi-mao Jiang,et al.  miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma , 2014, Journal of Cancer Research and Clinical Oncology.

[20]  D. Ma,et al.  The Overexpression of Scaffolding Protein NEDD9 Promotes Migration and Invasion in Cervical Cancer via Tyrosine Phosphorylated FAK and SRC , 2013, PloS one.

[21]  Liang Wang,et al.  Overexpression of NEDD9 is Associated with Altered Expression of E-Cadherin, β-Catenin and N-Cadherin and Predictive of Poor Prognosis in non-Small Cell Lung Cancer , 2013, Pathology & Oncology Research.

[22]  Zhaoshen Li,et al.  Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance , 2013, Tumor Biology.

[23]  D. Fan,et al.  Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma , 2013, Hepatology.

[24]  S. Iwata,et al.  Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer , 2012, Clinical Cancer Research.

[25]  Dimos Kapetis,et al.  NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma , 2012, Oncotarget.

[26]  Feng Gao,et al.  Expression and clinical significance of NEDD9 in lung tissues , 2012, Medical Oncology.

[27]  Shan Zhu,et al.  NEDD9 Is a Positive Regulator of Epithelial-Mesenchymal Transition and Promotes Invasion in Aggressive Breast Cancer , 2011, PloS one.

[28]  E. Golemis,et al.  NEDD9 and BCAR1 Negatively Regulate E-Cadherin Membrane Localization, and Promote E-Cadherin Degradation , 2011, PloS one.

[29]  Jasmin H. Bavarva,et al.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression , 2011, Oncogene.

[30]  J. Lucas,et al.  Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent , 2010, Oncogene.

[31]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[32]  Sun-Hee Kim,et al.  Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. , 2010, Cancer research.

[33]  M. Wolfson,et al.  NEDD9 promotes oncogenic signaling in mammary tumor development. , 2009, Cancer research.

[34]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[35]  E. Sahai,et al.  Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement , 2008, Cell.

[36]  P. Tugwell,et al.  Method guidelines for Cochrane Musculoskeletal Group systematic reviews. , 2006, The Journal of rheumatology.

[37]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[38]  E. Golemis,et al.  HEF1-Aurora A Interactions: Points of Dialog between the Cell Cycle and Cell Attachment Signaling Networks , 2006, Cell cycle.

[39]  E. Golemis,et al.  Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle. , 2005, Molecular biology of the cell.

[40]  Angela Wai-Man See,et al.  Crk‐associated substrate (Cas) family member, NEDD9, is regulated in human neuroblastoma cells and in the embryonic hindbrain by all‐trans retinoic acid , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[41]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[42]  S. Thompson,et al.  How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.

[43]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[44]  G. O'Neill,et al.  Proteolysis of the Docking Protein HEF1 and Implications for Focal Adhesion Dynamics , 2001, Molecular and Cellular Biology.

[45]  S. Kanner,et al.  Focal adhesion kinase regulates β1 integrin‐dependent T cell migration through an HEF1 effector pathway , 2001, European journal of immunology.

[46]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[47]  S. Iwata,et al.  Structure and function of Cas-L, a 105-kD Crk-associated substrate- related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes , 1996, The Journal of experimental medicine.

[48]  S. Kumar,et al.  Identification of a set of genes with developmentally down-regulated expression in the mouse brain. , 1992, Biochemical and biophysical research communications.

[49]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[50]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[51]  A. Gaponova,et al.  Preclinical and clinical studies of the NEDD 9 scaffold protein in cancer and other diseases , 2015 .

[52]  E. Golemis,et al.  HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells , 2007, Oncogene.

[53]  M. Einarson,et al.  Dissection of HEF1-dependent functions in motility and transcriptional regulation. , 2002, Journal of cell science.

[54]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.